Contact-Level ABM: How Precision Targeting Uncovers Buying Groups and Accelerates Pipeline

One of the most consequential ways in which B2B life science account-based marketing (ABM) programs fail to reach their goals is not through a lack of account engagement, but due to a gap in how effectively account engagement is turned into commercial traction. 

An account shows elevated activity. Website visits increase. A LinkedIn ad generates a click. The ABM platform flags the account as showing intent. And then the commercial team faces a question they cannot reliably answer: who, specifically, is driving that interest, what program or initiative is behind it, and who else in the organization is involved in the decision?

Without answers to those questions, the sales development representative (SDR) team is left to make educated guesses. Outreach goes to the most obvious contacts. The account gets marked as "being worked" in the CRM, and the opportunity either surfaces slowly through months of persistence or quietly stalls without ever becoming a pipeline opportunity.

Standard account-based marketing programs aim to provide some of this contextual information - the who, and that what they are engaging in - the what through engagement with specific ads and website pages, and the who through gated content form fills and CRM data. But the level of data provided is often limited to who is willing to fill out a form, or who is already in your CRM.

Contact-level ABM is the approach designed to solve this problem. This post explains why the challenge of identifying buying groups is uniquely complex in life sciences, and depends on knowing the “who” in detail, and how contact-level ABM can provide a much clearer picture of who at key accounts is likely to be specifically interested in your offering.

Why Life Science Accounts Are Not Single Buyers

To understand why contact-level ABM matters in life sciences specifically, it helps to be precise about the complexity of the organizations this sector typically targets.

A large pharmaceutical company is not one buyer. It is dozens of semi-independent buying groups, each organized around a specific program, asset, or functional initiative, each with its own budget, its own decision-making timeline, and its own set of vendor relationships. When an ABM platform flags that a major pharma is showing elevated engagement, that signal could be coming from any one of a large number of distinct programs operating simultaneously within the organization. Knowing the company is engaged tells you almost nothing about which program is driving the activity or who the relevant commercial stakeholders are.

Mid-size biotechs present a related but different challenge. These organizations are smaller and their programs fewer, but their commercial processes are often less structured, their organizational charts less transparent, and their personnel more fluid. A Series C biotech with two active clinical programs might have a buying group forming around one of those programs with no external signal that distinguishes it from general organizational activity.

Add in the complexity of acquisitions - where a biotech may now be part of a large pharma organization, but may still be operating effectively as an independent entity - and the picture of who the relevant in-market stakeholders are can become even harder to assemble.

In these cases, the account is the wrong unit of analysis. The group of people responsible for making decisions for the specific location, lab, or program - an in-market buying group - is the right one. The goal, then, is to determine the members of the buying group in order to connect with them and build a commercial opportunity. But even when you can craft a persona map of the titles and roles who are most likely to be part of a buying group, finding the exact right people can be challenging.

A Common Life Science Complexity: Many Relevant People, But Only One Relevant Program

Even when a life science company has been identified as a high-priority target, and even when signals show that a specific program is advancing, there remains a challenge that rarely gets discussed explicitly: within any moderately sized organization, there are likely multiple people who hold the same type of role.

A mid-size biotech with three active clinical programs might have three or four Clinical Program Directors. A large pharma will have dozens of scientists carrying Biomarker or Translational Medicine in their titles. A well-funded oncology-focused company could have several Heads of Clinical Operations. Knowing that a Clinical Program Director or a Biomarker Scientist is the right persona to target does not tell you which Clinical Program Director or which Biomarker Scientist is connected to the specific program that is in-market right now.

This is one of the most significant yet underappreciated challenges in life science commercial targeting. A database search filtered by title will return a list of plausible candidates. But candidates are not the same as the buying committee. The right person is somewhere in that list, but the list alone cannot tell you who it is.

Account-level ABM is limited in resolving this. Even when running persona-specific ads on LinkedIn to Clinical Program Directors, for example, all employees at an account will see the same ad. When someone clicks, you may know that a Clinical Program Director at a target account clicked, but you won’t know specifically which one. And in a large or mid-size organization, the difference between reaching out to the right Clinical Program Director and the wrong one can be the difference between a booked business meeting and no response.

How Contact-Level ABM Cuts Through the Complexity

Contact-level ABM creates a path through this complexity by operating at the individual level rather than the account or persona-category level. Engagement is tracked and attributed to specific named individuals rather than pooled into an account-level signal, giving your sales team a stronger picture of exactly the right people to reach out to, and what those people have shown interest in.

The underlying logic is that content relevance and program connection are closely related. A piece of content designed to speak directly to someone navigating a specific type of program challenge at a specific development stage will resonate most strongly with people who are actually working on that kind of program right now, or are about to. Someone who engages seriously and repeatedly with highly specific content is almost certainly doing so because it speaks to their current work. Someone who receives the same content and does not engage is less likely to be working in an area where that content is relevant, regardless of what their title says.

This means that engagement behavior, tracked at the individual level across a broad set of plausible candidates, becomes a way of filtering a list of possible buying committee members down to a much more targeted set of probable ones. The people who engage with the right content, at the right depth, within a concentrated timeframe, are most likely the people connected to the program that is in-market. Those who do not engage are probably not, at least not right now.

The result is something that could not be constructed from databases and organizational charts alone: an evidence-based picture of which individuals at a target account are likely part of the buying group for a specific program. This is why a contact-level ABM approach can provide more useful commercial data than standard ABM alone, and provides far more useful data than just pulling relevant titles from account databases.

What This Means for Sales and BD Outreach

The commercial value of all of this is ultimately realized in the quality and precision of the outreach it enables. And in life sciences, the difference between well-targeted and generic outreach is not a marginal improvement, it is often the difference between getting a response and not getting one.

Life science professionals are expert evaluators with limited time and limited patience for vendor outreach that does not demonstrate immediate relevance to what they are actually working on. An SDR who reaches out to the right person, knows what content that person has engaged with, and frames the conversation around the specific program challenge that content addressed is starting from a position of demonstrated relevance. That opening is qualitatively different from a cold sequence that begins with a generic capability overview.

The speed at which this outreach happens also matters. Buying groups in life sciences form and make decisions on program timelines. The window between a structural intent signal and the beginning of a formal vendor evaluation process is real and it closes. The commercial teams that are already in conversation with the right individuals when that process begins have an advantage. 

Contact-level ABM, done well, is what puts the right people in that conversation at the right time, and provides your sales team with the information that helps them be more effective, build pipeline, and win business.